Does Vascepa Affect Blood Pressure Differently Than Statins?
Vascepa (icosapent ethyl), a purified EPA omega-3 fatty acid, lowers triglycerides without raising blood pressure, unlike some statins that can slightly increase it. In the REDUCE-IT trial, Vascepa users saw no significant blood pressure change (systolic BP rose by 0.2 mmHg on average), while statins like atorvastatin in the trial increased systolic BP by 1.3 mmHg.[1][2] This difference stems from Vascepa's mechanism—reducing inflammation and triglycerides via EPA without the cholesterol synthesis inhibition that can elevate BP in statins.[3]
Why Do Statins Sometimes Raise Blood Pressure?
Statins lower LDL cholesterol by blocking HMG-CoA reductase but can cause small BP increases (1-4 mmHg systolic) in some patients, possibly from reduced endothelial nitric oxide or muscle effects. Meta-analyses show this in 10-20% of users, more common with high doses or lipophilic statins like simvastatin.[4] Vascepa avoids this, with trials reporting neutral or slight BP reductions in hypertensive patients.[2]
Clinical Trial Data on BP Changes
| Drug/Treatment | Trial | Systolic BP Change (mmHg) | Notes |
|---------------|--------|---------------------------|-------|
| Vascepa + statin | REDUCE-IT (n=8,179) | +0.2 | No increase; CVD risk cut 25%[2] |
| Placebo + statin | REDUCE-IT | +1.3 | Statin-driven rise[2] |
| Atorvastatin alone | Various meta-analyses | +1-2 | Dose-dependent[4] |
| Lovastatin | ASCOT-LLA | +2.5 | Vs placebo[5] |
Vascepa's BP neutrality holds across subgroups, including those with baseline hypertension.[1]
Patient Concerns: Who Might Notice BP Differences?
Patients on statins for high cholesterol often monitor BP due to potential rises, especially if diabetic or elderly. Switching to or adding Vascepa (for high triglycerides >150 mg/dL on statins) avoids this, per FDA approval. Real-world data shows Vascepa users report stable BP, with fewer discontinuations from vascular side effects.[6]
Alternatives if BP Rises on Statins
- Eicosapent ethyl (Vascepa): Preferred for TG>500 mg/dL; patent-protected until ~2030.[7]
- Rosuvastatin: Hydrophilic statin with minimal BP impact.
- Ezetimibe: Non-statin add-on, BP-neutral.
- PCSK9 inhibitors (e.g., Repatha): No BP effects but injectable and costly.
Consult a doctor for personalized switches; Vascepa requires CV risk factors for coverage.[1]
Sources
[1]: FDA Vascepa Label
[2]: NEJM REDUCE-IT
[3]: AHA Vascepa Statement
[4]: Hypertension Meta-Analysis
[5]: Lancet ASCOT-LLA
[6]: JACC Real-World
[7]: DrugPatentWatch.com - Vascepa